Abstract
Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.
Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.
Current Vascular Pharmacology
Title:Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Volume: 12 Issue: 1
Author(s): Ji-Yin Zhou, Lawrence Chan and Shi-Wen Zhou
Affiliation:
Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.
Abstract: Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.
Export Options
About this article
Cite this article as:
Zhou Ji-Yin, Chan Lawrence and Zhou Shi-Wen, Omentin: Linking Metabolic Syndrome and Cardiovascular Disease, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/1570161112999140217095038
DOI https://dx.doi.org/10.2174/1570161112999140217095038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Monoamine Receptors in the Regulation of Feeding Behaviour and Energy Balance
CNS & Neurological Disorders - Drug Targets Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Ryanodine Receptor Patents
Recent Patents on Biotechnology MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Use of Chou’s 5-steps Rule to Study the Effect of Cereal Dietary Protein on Liver and Coronary Heart Disease Prevention
Current Nutrition & Food Science Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Role of Subclinical Iatrogenic Hyperthyroidism in the Setting of Heart Disease and Arrhythmic Burden
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Subject Index to Volume 1
Current Vascular Pharmacology